- Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 12: Investigative Therapies in Recurrent Ovarian Cancer.
- Monk BJ, Coleman RL, Westin SN, Birrer MJ.
- OncLive. Peer Exchange. 2022 Nov 10.
- Video
- Free video
•• Original research:
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
•• Original research:
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
•• Commentary:
Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
•• Commentary:
Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.
•• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)
•• Original research:
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.